CURE’s thyroid cancer page is an extensive resource of cancer information featuring the latest thyroid cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on thyroid cancer.
July 11th 2025, 1:00pm
Survivors can find strength after cancer by focusing on goals, loved ones, and spiritual connection, especially during challenging or uncertain times.
July 2nd 2025, 1:00pm
Daniel Jernazian, who beat cancer twice, credits his sports mindset for survival and calls it winning his ‘life World Championship’.
January 31st 2025, 4:00pm
From the reveal of NBA star Dwyane Wade’s cancer surgery to a Bachelorette star on her husband’s cancer diagnosis, here is this week’s top cancer news.
December 3rd 2024, 4:00pm
Singer-songwriter Danielia Cotton, a thyroid cancer survivor and marathon runner shared how her experiences impact her art.
October 1st 2024, 3:00pm
Throughout September, the FDA approved drugs for the treatment of diseases including lung cancer, multiple myeloma, thyroid cancer and breast cancer.
September 27th 2024, 7:48pm
The approval of Retevmo is for the treatment of adults and children aged 2 years and older with advanced or metastatic medullary thyroid cancer.
September 19th 2024, 9:00pm
First-time treatment with Lenvima continues to outperform other treatments for thyroid cancer.
August 7th 2024, 3:00pm
Interventions, such as speech therapy, after receiving radioactive iodine treatment for thyroid cancer may help manage quality of life.
July 1st 2024, 7:00pm
The Food and Drug Administration issued six approvals for solid tumors in June, including thyroid, endometrial, colorectal, breast and ovarian cancers.
June 25th 2024, 3:00pm
An expert discusses the recent approval for Retevmo for RET-positive pediatric thyroid cancer and ongoing research for this patient population.
Gut Bacteria May Help Predict Heart Risks in Breast Cancer Treatment
Side Effects to Expect While on Datroway Treatment for Lung Cancer
Navigating EHE: Connecting with Experts and Support
Immunoglobulin Replacement Not Associated With Fewer Infections in CLL